Financial Tear Sheet

Corporate Profile

Founded in 2006, Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye.

The foundation of Ocular Therapeutix's pipeline is based on its proprietary, bioresorbable hydrogel technology that uses polyethylene glycol, or PEG, as a key component. The most advanced product candidate, currently in Phase 3 clinical development, is a drug-eluting intracanalicular depot containing the steroid dexamethasone for the treatment of ocular inflammation and pain following cataract surgery. Ocular also is evaluating a sustained released prostaglandin analog that can deliver treatment up to 90 days for the reduction of intraocular pressure for patients with glaucoma or ocular hypertension. All product candidates in the development pipeline are designed to replace weeks or months of dosing using existing pharmaceuticals and biologics with as little as a single dose administration. Earlier-stage product candidates are focused on the treatment of allergic and bacterial conjunctivitis and the company is also investigating intravitreal injections for wet age-related macular degeneration (AMD).

In January 2014, Ocular's ReSure® Sealant became the first and only FDA-approved sealant for ophthalmic use. The ReSure® Sealant is indicated for prevention of postoperative fluid egress from clear corneal incisions following cataract surgery is, one of the most commonly performed surgeries in the U.S. with about 3.5 million procedures performed annually.

Stock Performance

OCUL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	$9.96
Change (%)	▲ 0.07 (0.71%)
Volume	180,324
52 Week Low	$4.05
Market Cap	$289,120,713
Rolling EPS	-1.80
PE Ratio	0
Shares Outstanding	29,028,184

Data as of 04/28/17 4:00 p.m. ET

Recent Headlines & Events

04/24/17 - 8:00 a.m.
Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

04/06/17 - 8:00 a.m.
Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer

03/15/17 - 8:00 a.m.
New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix' DEXTENZA™ Following Cataract Surgery

There are currently no events scheduled.

SEC Filings

Filing Date	Form
04/20/17	DEF 14A
04/12/17	3
04/12/17	8-K
03/20/17	8-K

Corporate Governance

Amarpreet Sawhney, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors
Jim Fortune	Chief Operating Officer
Peter Jarrett, Ph.D.	Chief Technical Officer
Jonathan Talamo, M.D.	Chief Medical Officer
Eric Ankerud, J.D.	Executive Vice President, Clinical, Regulatory and Quality
Scott Corning	Vice President, Sales and Marketing
Art Driscoll	Vice President, Product Development

Data provided by Nasdaq. Minimum 15 minutes delayed.